Pharmahungary provides innovative preclinical and clinical R&D solutions for pharmaceutical, biotech and food supplement companies, focusing on cardiovascular (cardiovasc™, www.cardiovasc.com) and metabolic diseases such as diabetes, hyperlipidemia, atherosclerosis, obesity and aging. Our know-how in custom design innovative R&D model systems (innoRD™) significantly reduces the duration of your preclinical drug development. Pharmahungary’s high quality services are based on highly trained (in the US, Canada, UK, Germany) management team with recognized international expertise in preclinical and clinical pharmacology and medical sciences.

Pharmahungary runs some in-house R&D projects for the diagnosis and therapy of cardiovascular and metabolic diseases, currently focusing on the development of inhibitors of peroxynitrite (nitroscience™ project) and its downstream cellular target matrix metalloproteinases (MMPharma™ project), as well as activators of biglycan (biglycan™ project) for cardiovascular indications such as ischemic heart disease and atherosclerosis. Pharmahungary intends to license its new technologies and to develop joint venture R&D projects with pharmaceutical and biotechnological companies.

PharmaHungary™ is a member of the Hungarian Biotechnology Association and the Spin-off & Startup Company Association

Please contact us by e-mail or fax. Due to the large number of unsolicited phone calls, we take phone calls scheduled by prior e-mail correspondence only. Thank you for your understanding.

Please be informed, that Pharmahungary never sends bulk e-mails, however, unauthorized use of virtual Pharmahungary e-mail addresses may occur, we apologize for the inconvenience.